NasdaqGS:NBIXBiotechs
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR
In January 2026, Neurocrine Biosciences reported the first head-to-head PET imaging data showing INGREZZA (valbenazine) achieved substantially higher VMAT2 target occupancy and potency than rival AUSTEDO XR at therapeutic doses, with all regimens generally well tolerated.
The findings, highlighting INGREZZA’s stronger VMAT2 engagement potentially linked to its single high‑affinity metabolite, sharpen the clinical differentiation in treating tardive dyskinesia and Huntington’s disease chorea...